The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Erythromycin is an antibiotic used in the treatment or prevention of a wide range of bacterial infections. This antibiotic does not work in the event of viral infections such as common cold and flu. Erythromycin is thus used to treat respiratory tract infections, including bronchitis, pneumonia, Legionnaires' disease, and pertussis, diphtheria, as well as sexually transmitted diseases such as syphilis. It is also used to treat ear, intestine, gynecological, urinary tract, and skin infections. The erythromycin market is a rapidly growing market, as the drug is widely used across the globe and has been certified safe by the FDA.
Increasing prevalence of respiratory tract diseases due to growing volumes of toxic gases being let out in the environment is boosting demand for erythromycin, which in turn is fueling growth of the erythromycin market.
The downside of using this drug is that, it being an over-the-counter drug, it is often used for a variety of other purposes, even in mild cases or for non-bacterial infections. Using any antibiotic when it is not required causes the drug to not function for future infections. People thus, need to switch to other drugs instead of erythromycin. This in turn, poses a major restraint for growth of the erythromycin market.
Increasing number of companies are investing in the development of erythromycin owing to the lucrative opportunities, which in turn is augmenting growth of the erythromycin market.
In November 2017, Teligent, Inc.—a New Jersey-based specialty generic pharmaceutical company—received approval for its abbreviated new drug application (ANDA) from the U.S. FDA of Erythromycin Topical Solution USP, 2%. This approval accounted for Teligent’s eighth approval during the same year and eighteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.
In March 2018, Amneal Pharmaceuticals received FDA approval for Erythromycin Tablets USP for strengths of 250 mg and 500 mg. The Amneal product is a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available. The company sells its erythromycin tablets in 100-count bottles and has made them available to wholesalers, distributors, and direct to the trade.
Amneal aims at increasing access to affordable medications, and erythromycin tablets being products with limited availability, the company plans to benefit from the growing demand by providing patients and pharmacists with cost-effective options. According to January 2018 IQVIA market data, annual U.S. sales of erythromycin tablets accounted for US$ 84 million.
|Price : US$ 2,850||Date : Feb 2020|
|Category : Chemicals and Materials||Pages : 152|
|Price : US$ 3,000||Date : Jan 2019|
|Category : Healthcare and Pharmaceuticals||Pages : 146|
|Price : US$ 3,000||Date : Apr 2018|
|Category : Chemicals and Materials||Pages : 146|
|Price : US$ 2,800||Date : Nov 2017|
|Category : Healthcare and Pharmaceuticals||Pages : 104|
|Price : US$ 2,600||Date : Nov 2017|
|Category : Healthcare and Pharmaceuticals||Pages : 111|